AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Akero Therapeutics Inc (NASDAQ:AKRO)
-- USD
0.000 0.000%Sponsored Reports
Loading...
| Previous Close (in USD) | 54.65 |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 37.000/15.320 |
| EBITDA (in USD) | -269.266M |
| PE Ratio | -- |
| Volume | -- |
| Diluted Eps TTM | -3.78 |
| Total Assets (in USD) | 580.271M |
|---|---|
| Total Liabilities (in USD) | 44.965M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 234.207M |
| Market Cap (in USD) | 2,172.151 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Akero Therapeutics Inc
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
601 Gateway Boulevard, South San Francisco, CA, United States, 94080
650 487 6488
Employees: 60
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Andrew Cheng M.D., Ph.D. | Pres, CEO & Director | 1967 |
| 2. | Dr. Jonathan M. Young J.D., Ph.D. | Co-Founder, Exec. VP, COO & Sec. | 1970 |
| 3. | Dr. Timothy Rolph | Co-Founder & Chief Scientific Officer | 1954 |
| 4. | Mr. William R. White J.D. | Exec. VP, CFO, Treasurer & Head of Corp. Devel. | 1973 |
| 5. | Ms. Catriona Yale | Exec. VP & Chief Devel. Officer | 1972 |
| 6. | Mr. John J. Schembri | VP of Fin. & Controller | 1962 |
| 7. | Dr. Andrew Cheng M.D., Ph.D. | President, CEO & Director | 1967 |
| 8. | Dr. Jonathan M. Young J.D., Ph.D. | Co-Founder, Executive VP, COO & Secretary | 1970 |
| 9. | Mr. William R. White J.D. | Executive VP, CFO, Treasurer & Head of Corporate Development | 1974 |
| 10. | Ms. Catriona Yale | Executive VP & Chief Development Officer | 1972 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+0.422 0.962% | 44.69 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+0.400 0.909% | 44.4 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+5.575 1.253% | 446.685 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+1.910 0.312% | 613.35 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -112.033M | -100.777M | -79.207M | -43.755M | -81.714M |
| Minority Interest | - | - | - | - | 0M |
| Net Income | -108.91M | -100.736M | -79.19M | -43.755M | -81.714M |
| Selling General Administrative | 29.872M | 19.127M | 15.238M | 8.605M | 1.896M |
| Gross Profit | 115.156M | -100.886M | -80.154M | - | 0M |
| Reconciled Depreciation | 0.043M | 0.041M | 0.017M | - | - |
| Ebit | -115.156M | -100.927M | -80.171M | -43.755M | -13.778M |
| Ebitda | -111.294M | -100.886M | -80.154M | -45.651M | -81.714M |
| Depreciation And Amortization | 3.862M | 0.041M | 0.017M | - | -67.936M |
| Operating Income | -115.156M | -100.886M | -80.154M | -45.651M | -13.778M |
| Other Operating Expenses | 115.156M | 100.886M | 80.154M | 45.651M | 13.778M |
| Interest Expense | 0.739M | 0.041M | 0M | 0M | 0M |
| Tax Provision | - | - | - | - | - |
| Interest Income | - | - | - | - | 62.15M |
| Net Interest Income | -0.739M | - | - | - | - |
| Income Tax Expense | -3.123M | -0.041M | -0.017M | -1.896M | 0M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 115.156M | 100.886M | 80.154M | 45.651M | 13.778M |
| Cost Of Revenue | -115.156M | 100.886M | 80.154M | - | 0M |
| Total Other Income Expense Net | 3.123M | 0.109M | 0.947M | 1.896M | -67.936M |
| Net Income From Continuing Ops | -111.969M | -100.801M | -79.207M | -43.755M | -81.714M |
| Net Income Applicable To Common Shares | -112.033M | -100.777M | -79.207M | -43.755M | -82.234M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 580.271M | 356.57M | 195.548M | 273.339M | 138.118M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 9.952M | 3.724M | 5.324M | 2.958M | 1.649M |
| Total Liab | 44.965M | 30.008M | 26.439M | 14.627M | 9.392M |
| Total Stockholder Equity | 535.306M | 326.562M | 169.109M | 258.712M | 128.726M |
| Other Current Liab | 11.83M | 10.79M | 18.217M | 9.389M | 8.422M |
| Common Stock | 0.006M | 0.005M | 0.004M | 0.004M | 0.003M |
| Capital Stock | 0.006M | 0.005M | 0.004M | 0.004M | 0.003M |
| Retained Earnings | -574.096M | -422.337M | -310.304M | -209.527M | -130.32M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | 0.108M | 0.417M | 0.201M | 0.069M |
| Cash | 234.207M | 249.773M | 150.483M | 187.242M | 136.4M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 19.128M | 19.083M | 25.128M | 13.111M | 9.369M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -208.164M | -238.828M | -148.967M | -185.432M | -136.4M |
| Short Term Debt | 0.26M | 0.325M | 0.205M | 0.294M | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 26.043M | 10.945M | 1.516M | 1.81M | - |
| Other Stockholder Equity | 1109.126M | 748.857M | 479.436M | 468.238M | 120.931M |
| Property Plant Equipment | - | 0.047M | 0.09M | 1.793M | - |
| Total Current Assets | 559.962M | 355.173M | 193.582M | 271.345M | 138.049M |
| Long Term Investments | 19.283M | - | - | - | - |
| Short Term Investments | 315.803M | 101.676M | 37.775M | 81.145M | 71.612M |
| Net Receivables | - | - | 0.417M | 0.201M | - |
| Long Term Debt | 24.964M | 9.541M | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 7.038M | 7.968M | 6.706M | 3.428M | 0.947M |
| Accumulated Other Comprehensive Income | 0.27M | 0.037M | -0.027M | -0.003M | -0.006M |
| Non Currrent Assets Other | -0M | 0.108M | 0.417M | 0.201M | 0.069M |
| Non Current Assets Total | 20.309M | 1.397M | 1.966M | 1.994M | 0.069M |
| Capital Lease Obligations | 1.341M | 1.404M | 1.516M | 1.81M | - |
| Long Term Debt Total | - | 9.541M | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -63.825M | 42.28M | -9.761M | -71.513M | -71.513M |
| Total Cashflows From Investing Activities | -63.825M | 42.28M | -9.761M | -71.513M | -5M |
| Total Cash From Financing Activities | 255.632M | 0.602M | 203.107M | 95.988M | 85.007M |
| Net Income | -112.033M | -100.777M | -79.207M | -43.755M | -81.714M |
| Change In Cash | 99.29M | -36.799M | 122.542M | -11.152M | 75.382M |
| Begin Period Cash Flow | 150.591M | 187.39M | 64.848M | 76M | 0.618M |
| End Period Cash Flow | 249.881M | 150.591M | 187.39M | 64.848M | 76M |
| Total Cash From Operating Activities | -92.517M | -79.681M | -70.804M | -35.627M | -4.625M |
| Depreciation | 0.043M | 0.041M | 0.017M | -0.104M | 0.017M |
| Other Cashflows From Investing Activities | - | - | - | -71.513M | -5M |
| Dividends Paid | - | - | - | - | 0M |
| Change To Inventory | - | - | - | - | 0M |
| Sale Purchase Of Stock | 0.28M | 0.373M | 0.198M | 0.085M | 85.508M |
| Other Cashflows From Financing Activities | 14.547M | 0.229M | 0.355M | 0.451M | 85.007M |
| Capital Expenditures | 0M | 0M | 0.148M | 0.148M | 5M |
| Change In Working Capital | -4.459M | 9.727M | 2.085M | 6.462M | 1.061M |
| Other Non Cash Items | 0.689M | 0.203M | 0.196M | -0.104M | 75.907M |
| Free Cash Flow | -92.517M | -79.681M | -70.952M | -35.627M | -9.625M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | US Small-Cap Growth II Equity Comp | 1 year ago | 1814384 |
| 2. | T. Rowe Price New Horizons | 1 year ago | 1813206 |
| 3. | Janus Global Life Science AUSD | 1 year ago | 1495191 |
| 4. | Janus Henderson Glb Life Scn I2 USD | 1 year ago | 1368570 |
| 5. | SPDR® S&P Biotech ETF | 1 year ago | 973040 |
| 6. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 955892 |
| 7. | T. Rowe Price Health Sciences | 1 year ago | 760288 |
| 8. | Fidelity Small Cap Index | 1 year ago | 688960 |
| 9. | iShares Russell 2000 Value ETF | 1 year ago | 554768 |
| 10. | AB Small Cap Growth A | 1 year ago | 549964 |
| 11. | Wellington Global Hlthcr Eq USD G Ac | 1 year ago | 453903 |
| 12. | T. Rowe Price New Horizons Tr-Z | 1 year ago | 424815 |
| 13. | State St Russell Sm/Mid Cp® Indx NL Cl C | 1 year ago | 417085 |
| 14. | iShares Biotechnology ETF | 1 year ago | 395624 |
| 15. | AB Discovery Growth A | 1 year ago | 375777 |
| 16. | Vanguard Health Care Inv | 1 year ago | 4401168 |
| 17. | Janus Henderson Global Life Sciences | 1 year ago | 2013792 |
| 18. | Janus Henderson Global Life Sciences D | 1 year ago | 2013792 |
| 19. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 1926204 |
| 20. | iShares Russell 2000 ETF | 1 year ago | 1899131 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Wellington Management Company LLP | 1 year ago | 7896632 |
| 2. | HHG PLC | 1 year ago | 7077478 |
| 3. | RTW INVESTMENTS, LLC | 1 year ago | 5919435 |
| 4. | BlackRock Inc | 1 year ago | 5586637 |
| 5. | General Atlantic Llc | 1 year ago | 5233989 |
| 6. | T. Rowe Price Associates, Inc. | 1 year ago | 3808359 |
| 7. | Vanguard Group Inc | 1 year ago | 3676581 |
| 8. | Alkeon Capital Management, LLC | 1 year ago | 3325004 |
| 9. | State Street Corp | 1 year ago | 2502946 |
| 10. | AllianceBernstein L.P. | 1 year ago | 2017088 |
| 11. | Perceptive Advisors LLC | 1 year ago | 1714806 |
| 12. | Boxer Capital LLC | 1 year ago | 1676733 |
| 13. | Geode Capital Management, LLC | 1 year ago | 1571012 |
| 14. | Redmile Group, LLC | 1 year ago | 1387479 |
| 15. | Point72 Asset Management, L.P. | 1 year ago | 1303323 |
| 16. | T. Rowe Price Investment Management,Inc. | 1 year ago | 1300096 |
| 17. | Baker Bros Advisors LP | 1 year ago | 1097082 |
| 18. | Rock Springs Capital Management LP | 1 year ago | 933399 |
| 19. | Logos Global Management LP | 1 year ago | 800000 |
| 20. | Yiheng Capital LLC | 1 year ago | 758769 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...